Aurobindo Pharma today said the US health regulator has lifted the import alert on its Hyderabad-based antibiotics facility, thereby allowing the company to export 9 products from this plant to the US market. US Food and Drug Administration (USFDA) has lifted the import alert for non-sterile products manufactured at Unit-VI cephalosporin facility based in Hyderabad, thereby, paving the way for resumption of exports of 9 products to the US market, Aurobindo Pharma LtdBSE 11.67 % said in a statement. "Prior to import alert, the unit was having annual US sales of USD 33 million for the said products," it added. In 2011, the USFDA had issued an import alert on products from the company's Hyderabad-based cephalosporin facility, as a result of which its exports to the US market were affected.